CMPX
Compass Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CMPX
Compass Therapeutics, Inc.
A clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases
Pharmaceutical
03/20/2018
11/02/2021
NASDAQ Stock Exchange
35
12-31
Common stock
80 Guest Street, Suite 601, Boston, Massachusetts 02135
--
Compass Therapeutics, Inc., was originally incorporated in Delaware on March 20, 2018 as Olivia Ventures, Inc. On June 17, 2020, the company changed its name to Compass Therapeutics, Inc. The Company is a clinical-stage biopharmaceutical company developing proprietary antibody therapies designed to harness the immune system for the treatment of solid tumors and hematological malignancies. The company's immuno-oncology product candidates include clinical-stage monoclonal antibodies and bispecific antibody combinations. These product candidates are designed to address three key components required for an effective immune response to cancer: inducing a strong innate immune response; activating the adaptive immune system; and mitigating immunosuppressive mechanisms by which tumors evade immune surveillance and activation.
Company Financials
EPS
CMPX has released its 2025 Q3 earnings. EPS was reported at -0.08, versus the expected -0.13, beating expectations. The chart below visualizes how CMPX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
